Literature DB >> 29534955

Intramural Metastasis as a Risk Factor for Recurrence in Esophageal Squamous Cell Carcinoma.

Duk Hwan Moon1, Jae Hyun Jeon2, Hee Chul Yang1, Young-Il Kim1, Jong Yeul Lee1, Moon Soo Kim1, Jong Mog Lee1, Geon-Kook Lee1.   

Abstract

BACKGROUND: The purpose of this study was to assess the clinicopathologic implications of intramural metastasis (IM) in patients with esophageal squamous cell carcinoma (ESCC).
METHODS: We retrospectively analyzed 743 patients who underwent esophagectomy. Among these patients, IM was detected in 41 patients (5.5%). The clinicopathologic features of IM and its influence on postoperative recurrence were investigated.
RESULTS: In total, 710 male patients and 33 female patients with a mean age of 64.4 ± 7.7 years were included. The median follow-up period was 98.5 months. IM was associated with large tumor size (p < 0.001), advanced T stage (p < 0.001), advanced N stage (p < 0.001), and advanced histologic grade (p < 0.023). IM was detected preoperatively in 51.2% of patients, and the median size of the metastasis was 2.0 cm (range: 0.1 to 6.4 cm). The median distance from the primary tumor to the metastasis was 2.5 cm (range: 0.5 to 21.0 cm); multiple metastases were observed in 46.3% of patients. Multivariable analyses revealed that advanced T stage (p < 0.001), advanced N stage (p < 0.001), and IM presence (p = 0.002) were independent risk factors for recurrence. The 5-year recurrence-free survival was 6.1% for patients with IM and 43.5% for patients without IM (p < 0.001).
CONCLUSIONS: IM could be an important prognostic factor, along with anatomic determinants such as the TNM staging system, in patients with ESCC. Effective preoperative evaluation and postoperative surveillance may help improve the outcome of patients with ESCC, particularly when accompanied by IM.
Copyright © 2018 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 29534955     DOI: 10.1016/j.athoracsur.2018.02.018

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  6 in total

1.  Significance of Intramural Metastasis in Patients with Esophageal Squamous Cell Carcinoma: An Indicator of Aggressive Cancer Behavior.

Authors:  Akihiko Okamura; Masayuki Watanabe; Ryotaro Kozuki; Tasuku Toihata; Keita Takahashi; Yu Imamura; Shinji Mine
Journal:  World J Surg       Date:  2019-08       Impact factor: 3.352

2.  Treatment Strategy for Esophageal Squamous Cell Carcinoma With Endoscopic Intramural Metastasis.

Authors:  Akihiko Okamura; Shoichi Yoshimizu; Jun Kanamori; Yu Imamura; Takao Asari; Izuma Nakayama; Mariko Ogura; Akiyoshi Ishiyama; Toshiyuki Yoshio; Keisho Chin; Junko Fujisaki; Masayuki Watanabe
Journal:  Cureus       Date:  2022-03-10

3.  Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy.

Authors:  Sho Okuda; Kenoki Ohuchida; Koji Shindo; Taiki Moriyama; Jun Kawata; Koji Tamura; Masafumi Sada; Kinuko Nagayoshi; Yusuke Mizuuchi; Naoki Ikenaga; Kohei Nakata; Yoshinao Oda; Masafumi Nakamura
Journal:  Oncol Lett       Date:  2022-08-11       Impact factor: 3.111

4.  Arterial Infusion Chemotherapy for Neoplastic Esophagogastric Anastomotic Strictures After Esophagectomy.

Authors:  Pengfei Xie; Meipan Yin; Wei He; Yaozhen Ma; Chunxia Li; Zhen Li; Xiaobing Li; Shuai Wang; Gang Wu
Journal:  Front Oncol       Date:  2021-05-26       Impact factor: 6.244

5.  XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.

Authors:  Jie Jian; Shuang Li; Li-Zhen Liu; Li Zhen; Ling Yao; Li-Hong Gan; Ya-Qing Huang; Nian Fang
Journal:  Int J Mol Med       Date:  2020-05-04       Impact factor: 4.101

6.  Patterns of distant metastases in patients with clear cell renal cell carcinoma--A population-based analysis.

Authors:  Jianxin Xue; Wensun Chen; Wenbo Xu; Zicheng Xu; Xiao Li; Feng Qi; Zengjun Wang
Journal:  Cancer Med       Date:  2020-11-28       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.